APPENDIX B: MedDRA CONCEPT DESCRIPTIONS
This appendix provides a list of MedDRA concept descriptions. A concept description is a description of how a concept is interpreted, used, and classified within the MedDRA terminology and is not a definition. The concept descriptions are intended to aid the consistent and accurate use of MedDRA in coding, retrieval, and analysis and to overcome the differences of medicine practice worldwide. The MSSO expects this appendix to be a working document and grow as subscribers request additional concepts to be documented.
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Abuse
For the purposes of term selection and analysis of MedDRA-coded data, abuse is the intentional, non-therapeutic use by a patient or consumer of a product – over-the counter or prescription – for a perceived reward or desired non-therapeutic effect including, but not limited to, “getting high”(euphoria). Abuse may occur with a single use, sporadic use or persistent use of the product.
Acute
For use in medicine, the word means “reaching a crisis rapidly.” In some instances, an “acute” condition may be interpreted as more severe than a “chronic” one. This was considered during the processing of proposed modified terms to assure that terms expressing only severity were not included.
Addiction
For the purposes of term selection and analysis of MedDRA-coded data, addiction is an overwhelming desire by a patient or consumer to take a drug for non-therapeutic purposes together with inability to control or stop its use despite harmful consequences. Addiction can occur because drug induces physical dependence and consequently a withdrawal syndrome, but this is not an essential feature; and addiction can occur because of a desire to experience the drug's psychological, behavioral or physical effects.
Aggravated
From “aggravate”: To make worse, e.g., “bronchitis aggravated by smoking.” For the purposes of term placement in MedDRA, the use of modifiers exacerbated, aggravated and worsened is interchangeable
Application site
For the purposes of MedDRA, an application site is considered to be the surface that contacts a topical medication in the form of a cream, lotion, or patch (e.g., an estrogen hormone patch). It does not pertain to other methods of drug delivery such as injection or infusion by catheter or other means.
Angina
“Angina” exists in MedDRA as a non-current LLT because of the ambiguous nature of the term. Angina is interpreted as a variant expression for acute tonsillitis (angina tonsillaris) in certain languages. However, based on the popular usage of this term in English language for Angina pectoris, in MedDRA it is linked to PT Angina pectoris.
Arthritis/Arthrosis
In MedDRA, any inflammation of a joint is considered “arthritis.” In
contrast “arthrosis” is interpreted as a non-inflammatory degenerative joint
disease and is linked to PT Osteoarthritis.
Cancer/Carcinoma
"Cancer" is a disease in which abnormal cells divide uncontrollably
and can spread to other parts of the body (metastasize).
"Cancer" can be one of several histologic types including those
derived from epithelial tissues (carcinomas), those derived from mesenchymal
tissue (sarcomas), and those arising from hematopoietic and lymphoid tissues
(leukemia, lymphomas, and multiple myeloma). In the context of MedDRA,
"carcinoma" and "cancer" are considered synonymous.
“Carcinoma" terms are generally subordinate to "cancer" terms
(e.g., LLT Skin carcinoma is linked to PT Skin cancer).
Cell marker
A cell marker is a biochemical or genetic characteristic of a cell which discriminates between different cell types.
Chronic
Of long duration; subject to a disease or habit for a long time. In some instances, a “chronic” condition may be interpreted as milder than an “acute” one. This was considered during the processing of proposed modified terms to assure that terms expressing only severity were not included.
Closure
Closure is the cap, lid, stopper or other feature which is the primary mechanism for protecting the product from spill, air etc.
Cold
For purposes of MedDRA, the mention of “cold” without addition of any prefix of feeling signifies the catarrhal disorder associated with nasopharyngitis. “Coldness” and “feeling cold,” are body temperature perceptions of uncomfortably low
temperature for humans.
Compounding
Compounding refers to products that are usually made by a pharmacist or physician.
Compounding
issue
Compounding issue refers to quality problems associated with those products.
Contributing factor
A contributing factor is a circumstance, action or influence which is thought to have played a part in the origin or development of a medication error or to increase the risk of a medication error.
Coring
A small piece of the stopper is sometimes sheared off (known as coring); an
example could be after a needle is inserted through the stopper of a medication
vial.
Crystal
formation
Crystals are symmetrically arranged formations created by the solidification of
a chemical element, a compound, or a mixture found in or on the dosage form
which is not normal for the product.
Device capture
PT Device capturing issue refers to a situation where a device fails capture signal input or output, or captures the wrong signal input or output.
Device use error
An act or omission of an act that results in a different medical device response than intended by the manufacturer or expected by the operator.
Diaphragm
For purposes of MedDRA, diaphragm is considered a respiratory structure.
Dispensing
Error
Dispensing errors are not limited to pharmacists. It can include nurses
and physicians. For example, physicians can dispense sample products in
their office.
Dissolution
Dissolution is the process in which one substance is dissolved in another. Dissolution and solubility are considered synonyms in MedDRA.
Dosage
The determination and regulation of the size, frequency, and number of doses.
Dosage Form
The physical form in which a drug is produced for administration to recipient
(tablets, capsules, cream etc.).
Dose
A quantity to be administered at one time, such as a specified amount of medication.
Dose Omission
Dose omission refers to an event where an ordered dose is not administered before the next scheduled dose, if any.
Documented
hypersensitivity to administered drug
This medication error refers to the situation when a patient is administered a
drug that is documented in the patient's medical file to cause a
hypersensitivity reaction in the patient. Example: Despite the fact
that the patient's medical record indicated "sulfa allergy," the
physician prescribed a sulfa antibiotic. Subsequently, the patient took the
antibiotic and experienced hives. A related term, PT Documented
hypersensitivity to administered product, applies to similar situations
involving known hypersensitivity to other types of products, not specifically
drugs.
Drug
diversion
For the purposes of term selection and analysis of MedDRA-coded
data, drug diversion means that a drug is diverted from legal and medically
necessary uses toward illegal uses.
Drug
Formulation
Refers to both active and inactive ingredients.
Duration
Includes duration of therapy/length of therapy.
Exacerbation
See “Aggravated.” For the purposes of term placement in MedDRA,
the use of modifiers exacerbated, aggravated and worsened is
interchangeable
Exposure
For the purposes of MedDRA, the concept of “exposure”:
· Is not limited to drugs; it can include exposure to chemicals, toxins, radiation, communicable disease, etc.
· Can occur through various pathways (via blood, direct contact, etc.)
Extension
When paired with a product or a device, an extension is a component of a device
that carries the impulses from the implant site of a device to the lead.
Gel
Formation
A product has formed into a gelatinous matter, a colloid in a more solid form
than a solution which is not normal for the product.
H
High Blood
Pressure
“High” and “low” terms in MedDRA are generally considered to be
laboratory/investigation type of terms and are found in the SOC Investigations.
However, because of the synonymous use of expression blood pressure high and
hypertension in common usage, the LLT Blood pressure high is
linked to PT Hypertension in SOC Vascular disorders.
Hypertension
vs. Hypertonia
Hypertonia” may be synonymous for “hypertension” in some languages.
However, for purposes of MedDRA, hypertonia is defined as a condition marked by
an abnormal increase in muscle tension and a reduced ability of a muscle to
stretch. Hence, it is placed in muscle tone disorders.
Hy's Law
Hy's law is used as an indicator for potential drug-induced liver injury. To be
considered a potential “Hy's law” case, the following three components must all
be met:
· Elevation of aminotransferases, e.g., alanine aminotransferase (ALT) and aspartate aminotransferase (AST), of >3x upper limit of normal (ULN)
· Alkaline phosphatase (ALP) <2x ULN
· Increase in total bilirubin ≥2x ULN
Please refer to the July 2009 FDA Guidance for Industry – “Drug-Induced Liver Injury: Premarketing Clinical Evaluation” for additional information.
Inappropriate
Schedule
Includes all deviations from the prescribed dosage schedule.
Intercepted medication error
For the purposes of term selection and analysis of MedDRA-coded data, an
intercepted medication error refers to the situation where a medication error
has occurred but is prevented from reaching the patient or consumer. The
intercepted error term should reflect the stage at which the error occurred,
rather than the stage at which it was intercepted.
Issue
The word “issue” for the purpose of MedDRA is used as a general term, which
does not necessarily point to a failure or defect when paired with a product or
a device.
Label
Label refers to display of written, printed, or graphic matter upon the
container or packaging.
Labelled
drug-disease interaction medication error
This medication error refers to the situation when a patient is prescribed,
dispensed, or administered a drug that is documented in the drug label as
having the potential to exacerbate or worsen the patient's pre-existing
disease(s). Example: A patient has a medical history of having bleeding
gastric ulcers. However, the patient was inadvertently prescribed and dispensed
several doses of aspirin.
Labelled
drug-drug interaction medication error
This medication error refers to the situation when a patient is prescribed,
dispensed, or administered a drug that is documented in the drug label to cause
a drug to drug interaction with the patient's existing medication(s).
Example: Patient became pregnant whilst taking an antifungal drug and an oral
contraceptive. This interaction is clearly stated in the product data
sheet.
Labelled
drug-food interaction medication error
This medication error refers to the situation when a patient is prescribed,
dispensed, or administered a drug that is documented in the drug label to cause
an expected adverse event with patient's consumed food. Example: Patient
drank grapefruit juice whilst taking a calcium channel blocker and the calcium
channel blocker is labeled for grapefruit juice interaction.
Labelled drug-genetic interaction medication error
This medication error refers to the situation when a patient is prescribed, dispensed, or administered a drug that is documented in the drug label to cause an interaction in patients with particular genetic variants. Example: Patient was inadvertently given a drug that is contraindicated in patients who are cytochrome P450 2D6 poor metabolisers.
Lower
gastrointestinal tract
For purposes of MedDRA, the following constitute the lower gastrointestinal
tract: small intestine (duodenum, jejunum, ileum) and large intestine which
includes cecum (and the vermiform appendix attached to the cecum), colon
(ascending colon, transverse colon, descending colon and sigmoid flexure),
rectum, and anus.
Lower
respiratory tract
For purposes of MedDRA the lower respiratory tract is comprised of
bronchi, bronchioles, alveoli and lungs.
Manufacturing stability testing
For the purposes of term selection and analysis of MedDRA-coded data, manufacturing stability testing refers to the stage of the manufacturing process where testing is performed to provide evidence on how the quality of a drug substance or drug product varies with time under the influence of a variety of environmental factors such as temperature, humidity, and light. Stability testing permits the establishment of recommended storage conditions, retest periods and shelf lives.
Medication
error
For the purposes of term selection and analysis of MedDRA-coded data,
medication errors are defined as any unintentional
and preventable event that may cause or lead to inappropriate
medication use or patient harm while the medication is in the control of the
health care professional, patient or consumer. Such events may be related
to professional practice, health care products, procedures and systems,
including prescribing, order communication, product labeling, packaging and
nomenclature, compounding, dispensing, distribution, administration, education,
monitoring and use.
Medication
monitoring error
For the purposes of term selection and analysis of MedDRA-coded
data, a medication monitoring error is an error that occurs in the process of
monitoring the effect of the medication through clinical assessment and/or
laboratory data. It can also refer to monitoring errors in following
instructions or information pertinent to the safe use of the medication.
Misuse
For the purposes of term selection and analysis of MedDRA-coded data, misuse is
the intentional use for a therapeutic purpose by a patient or consumer of a
product – over-the-counter or prescription – other than as prescribed or not in
accordance with the authorised product information.
Occupational
exposure
Occupational exposure encompasses the “chronic” exposure to an agent (including
therapeutic products) during the normal course of one's occupation and could
include additional scenarios in specific regulatory regions. For example,
occupational exposure may additionally relate to a more acute, accidental form
of exposure that occurs in the context of one's occupation.
Off Label
Use
For the purposes of term selection and analysis of MedDRA-coded data, the
concept of “off label use” relates to situations where a healthcare
professional intentionally prescribes, dispenses, or recommends a product for a
medical purpose not in accordance with the authorised product information. When
recording off label use, consider that product information and/or
regulations/requirements may differ between regulatory regions.
Out of specification test results
For the purposes of term selection and analysis of MedDRA-coded data, out of specification test results refers to test results performed during the pharmaceutical product manufacturing process that fall outside the specifications or acceptance criteria established in drug applications, drug master files, official compendia, or by the manufacturer. It also applies to all-in process laboratory tests that are outside of established specifications.
Overdose
For the purposes of term selection and analysis of MedDRA-coded data, overdose
is more than the maximum recommended dose (in quantity and/or concentration),
i.e., an excessive dose.
Precipitate
Precipitate is substance separated from a solution or suspension by chemical or physical change usually as an insoluble solid which is not normal for the product.
Preparation
A medicinal substance that is ready for use (e.g., a preparation for colds).
http://www.merriam-webster.com/medical/preparation
Prescribing
error
Prescribing errors may be made in the hand of physicians or other healthcare
professionals who have the prescription authority.
Procedure
This term relates to concepts currently in SOC Injury, poisoning and
procedural complications under HLGT Procedural related
injuries and complications NEC and in SOC Surgical and medical
procedures.
Product
In the context of MedDRA, "product" can refer to various types of
products intended for human use such as drugs (prescription and over the
counter), biologics, vaccines, combination products, devices, nutraceuticals,
dietary supplements, etc.
Product
coating incomplete
Product coating incomplete refers to the outer coating of a product when it
does not entirely cover the product and can appear blotchy, splattered or
speckled.
Product
colour issue
Product color issue is when the product color is not uniform; color has faded
or turned to a different color/shade.
Product
dosage form confusion
Product dosage form confusion is a misinterpretation of the dosage form of a
product which may potentially result in a medication error.
Product
label confusion
Product label confusion is a misinterpretation of the appearance and/or content
of a product label which may potentially result in a medication error. This may
be due to similarity with another product's label or due to confusing
information on a single product label.
Product
name confusion
Product name confusion is a misinterpretation of the correct name of a product
which may result in a medication error. This may be due to a misleading name,
or due to similar-looking or sounding product names.
Product odour abnormal
A change in the normal odor of the product.
Product
packaging confusion
Product packaging confusion is a misinterpretation of the appearance of a
product's packaging which may potentially result in a medication error. This
may be due to similarity with the appearance of another product's packaging or
due to confusing appearance or presentation of a single product's packaging.
Product
quality issues
Product quality issues are abnormalities that may be introduced
during the manufacturing/labeling, packaging, shipping, handling or storage of
the products.
Product storage
HLT Product distribution and storage issues in SOC Product issues is intended to cover issues with the storage of products by manufacturers, distributors, wholesalers, etc. In contrast, product storage issues by end-users such as healthcare professionals, patients, and consumers are considered to be medication errors and are represented by the appropriate medication error terms in HLT Product storage errors and issues in the product use system in SOC Injury, poisoning and procedural complications.
Product taste abnormal
A change in the normal taste of the product.
Progression
of
Movement forward; advancement. Continuously spreading or increasing in
severity.
Prophylaxis
of
Protective treatment for or prevention of disease. For the purposes of
term placement in MedDRA, the use of modifiers “prophylaxis” and “prevention
of” is interchangeable.
Rate
The amount of drug (dose) administered per unit of time
Recurrent
Occurring or appearing again or repeatedly. For the purposes of term placement in MedDRA, the modifiers “relapse” and “recurrent” are synonymous.
Seal
A seal refers to an outer wrap on the closure or a liner attached to the
container underneath the closure to either protect the product or act as a
tamper evident feature.
Sedimentation
Sedimentation is the settling of product or foreign material to the bottom of a
vial/container which is not normal for the product.
Sore/soreness/sores
For purposes of MedDRA, “sore” and “soreness” terms are used for
pain. “Sore” terms, unless clearly addressed to a concept e.g. LLT Bed
sore linked to PT Decubitus ulcer – are mainly placed under either pain related
PTs or PTs indicating inflammation. “Sores” are considered lesions of the skin
or mucous membrane frequently associated with pain, inflammation etc.,
depending on the context.
Solubility
See the concept description for dissolution.
Strength
Refers to a concentration of active ingredient found in a particular dosage form.
Subacute
Between acute and chronic: course of a disease of moderate duration or severity. Please see definitions of “acute” and “chronic.”
Technique
The manner of performance, method, operation, procedure, or details (e.g., pharmaceutical technique, aseptic technique) used to prepare a product.
Tenderness
For purposes of MedDRA tenderness terms are defined as sub-concepts of pain and mainly subordinated to “Pain” or to “-algia” PTs unless they clearly address a single concept (e.g., PT Abdominal rebound tenderness).
Thrombophlebitis
Inflammation of a vein (phlebitis) associated with thrombus formation
(thrombosis). The MSSO acknowledges the international use of
thrombophlebitis/phlebothrombosis/vein thrombosis interchangeably, but MedDRA
recognizes them as separate unique concepts. MedDRA also makes a distinction
between superficial and deep vein thrombosis. When thrombosis occurs in the
lower extremity, it is often called deep venous thrombosis/thrombophlebitis
(DVT); when superficial vessels are involved, it is superficial
thrombosis/thrombophlebitis.
Underdose
For the purposes of term selection and analysis of MedDRA-coded data, underdose is the administration of less than the minimum recommended dose (in quantity and/or concentration).
Upper
gastrointestinal tract
In MedDRA the following organs constitute the upper gastrointestinal tract:
mouth (buccal cavity; including salivary glands, mucosa, teeth, and tongue),
oesophagus and stomach which includes the cardia, fundus, body, and pylorus.
Upper
respiratory tract
In MedDRA the upper respiratory tract is comprised of nose, paranasal sinuses,
pharynx, larynx and trachea.
Worsened/worsening
See “aggravated.” For the purposes of term placement in MedDRA, the use
of modifiers exacerbated, aggravated, and worsened is interchangeable.